Parliament Panel Criticizes Delay Of India Drugs Policy
This article was originally published in PharmAsia News
Executive Summary
A Parliament panel is critical of India's drug department for delaying the final version of the National Pharmaceutical Policy 2006. The policy is intended to lower the price of drugs through expanded price controls. The Parliamentary Standing Committee on Chemical and Fertiliser noted the department had strongly endorsed the proposed policy in an annual report, but said the agency had done little since, holding only three meetings on the matter. The committee said part of the budget intended to follow up on the policy remains unspent while the policy review continues without end. (Click here for more
You may also be interested in...
Who’s Hired? Hikma Recruits New US Generics President
A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.
Organon And Henlius Complete Phase III For Denosumab
Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.
Taro Agrees $36m Securities Settlement Over US Price-Fixing Claims
Sun’s Taro subsidiary is looking to move forward with an eight-figure settlement deal in the US, after plaintiffs including a firefighters’ pension fund accused the firm of misleading investors via its involvement in generic price fixing, leading to a fall in the price of its securities.